FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Helmut Maecke

Research Profile

Chemicals & Drugs

Concepts & Ideas

Tissue Distribution

Living Beings

Disorders

Procedures

Positron-Emission Tomography

Co-author Network

Publications

TOP 3
Nicolas Marincek; Jan Müller-Brand; Christoph Rochlitz; Christian Schindler; Matthias Briel; Philippe Brunner; Ann-Catherine Jörg; Michael T Koller; Helmut R Maecke; Martin A Walter
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study.
Flavio Forrer; Helmut R Maecke; Jan Mueller-Brand; C Oechslin-Oberholzer; B Campana; Andreas Lohri
Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab.
Ariane Boubaker; Sébastien Baechler; Angelika Bischof Delaloye; Melanie Champendal; Mihaela Ginj; Marek Kosinski; Helmut R Maecke; John O Prior; Jean-Pierre Willi; Franz Buchegger
Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Helmut Maecke (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nicolas Marincek; Jan Müller-Brand; Christoph Rochlitz; Christian Schindler; Matthias Briel; Philippe Brunner; Ann-Catherine Jörg; Michael T Koller; Helmut R Maecke; Martin A Walter
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study.
Journal of translational medicine 2013;11():17.
2012: Flavio Forrer; Helmut R Maecke; Jan Mueller-Brand; C Oechslin-Oberholzer; B Campana; Andreas Lohri
Is there need for radioimmunotherapy? results of a phase I/II study in patients with indolent B-cell lymphomas using lutetium-177-DOTA-rituximab.
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology 2012;56(6):544-50.
2012: Ariane Boubaker; Sébastien Baechler; Angelika Bischof Delaloye; Melanie Champendal; Mihaela Ginj; Marek Kosinski; Helmut R Maecke; John O Prior; Jean-Pierre Willi; Franz Buchegger
Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide.
European journal of nuclear medicine and molecular imaging 2012;39(12):1868-75.
2012: Xuejuan Wang; Melpomeni Fani; Jean Claude Reubi; Jean Rivier; Stefan Schulz; Helmut R Maecke
Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.
European journal of nuclear medicine and molecular imaging 2012;39(12):1876-85.
2012: Melpomeni Fani; Helmut R Maecke; Jean E Rivier; Beatrice Waser; Wolfgang A Weber; Karin Beetschen; Friederike Braun; Renzo Cescato; Judit Erchegyi; Jean Claude Reubi
Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012;53(9):1481-9.
2012: Melpomeni Fani; Elisabeth Lasri; Christelle Medina; Guillaume P Nicolas; Marc Port; Isabelle Raynal; Maria-Luisa Tamma; Wolfgang A Weber; Helmut R Maecke
In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
Molecular pharmaceutics 2012;9(5):1136-45.
2012: Milan Laznicek; Alice Laznickova; Helmut R Maecke
Receptor affinity and preclinical biodistribution of radiolabeled somatostatin analogs.
Anticancer research 2012;32(3):761-6.
2012: Melpomeni Fani; Helmut R Maecke
Radiopharmaceutical development of radiolabelled peptides.
European journal of nuclear medicine and molecular imaging 2012;39 Suppl 1():S11-30.
2012: Hanwen Zhang; Keelara Abiraj; Michael Honer; Jean Claude Reubi; Peter Smith-Jones; Daniel L J Thorek; Beatrice Waser; Helmut R Maecke
Evolution of bombesin conjugates for targeted PET imaging of tumors.
PloS one 2012;7(9):e44046.
2011: Keelara Abiraj; Renzo Cescato; Melpomeni Fani; Flavio Forrer; Rosalba Mansi; Guillaume Nicolas; Jean Claude Reubi; Maria-Luisa Tamma; Helmut R Maecke
Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(12):1970-8.
2011: Damian Wild; Martin Behe; Ingo Brink; Melpomeni Fani; Helmut R Maecke; Jean Claude Reubi; Jean E F Rivier; Wolfgang A Weber
First clinical evidence that imaging with somatostatin receptor antagonists is feasible.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(9):1412-7.
2011: Rebecca A Dumont; Roland Haubner; Helmut R Maecke; Wolfgang A Weber; Friederike Deininger; Melpomeni Fani
Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(8):1276-84.
2011: Melpomeni Fani; Keelara Abiraj; Renzo Cescato; Luigi Del Pozzo; Rosalba Mansi; Jean Claude Reubi; Maria Luisa Tamma; Beatrice Waser; Wolfgang A Weber; Helmut R Maecke
PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(7):1110-8.
2011: Helmut R Maecke; Jean Claude Reubi
Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(6):841-4.
2011: Petra Kolenc-Peitl; Rosalba Mansi; MariaLuisa Tamma; Tanja Gmeiner-Stopar; Marija Sollner-Dolenc; Beatrice Waser; Richard P Baum; Jean Claude Reubi; Helmut R Maecke
Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor.
Journal of medicinal chemistry 2011;54(8):2602-9.
2011: Damian Wild; Michael Frischknecht; Hanwen Zhang; Alfred Morgenstern; Frank Bruchertseifer; Julie Boisclair; Anne Provencher-Bolliger; Jean-Claude Reubi; Helmut R Maecke
Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
Cancer research 2011;71(3):1009-18.
2011: Hanwen Zhang; Maxim A Moroz; Inna Serganova; Thomas Ku; Ruimin Huang; Jelena Vider; Helmut R Maecke; Steven M Larson; Ronald Blasberg; Peter Smith-Jones
Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOC.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(1):123-31.
2011: Melpomeni Fani; Xuejuan Wang; Guillaume Nicolas; Christelle Medina; Isabelle Raynal; Marc Port; Helmut R Maecke
Development of new folate-based PET radiotracers: preclinical evaluation of ⁶⁸Ga-DOTA-folate conjugates.
European journal of nuclear medicine and molecular imaging 2011;38(1):108-19.
2011: Rosalba Mansi; Xuejuan Wang; Flavio Forrer; Beatrice Waser; Renzo Cescato; Keith Graham; Sandra Borkowski; Jean Claude Reubi; Helmut R Maecke
Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours.
European journal of nuclear medicine and molecular imaging 2011;38(1):97-107.
2010: Melpomeni Fani; Andreas Mueller; Maria-Luisa Tamma; Guillaume Nicolas; Hans R Rink; Renzo Cescato; Jean Claude Reubi; Helmut R Maecke
Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2010;51(11):1771-9.
2010: Beatrice Waser; Renzo Cescato; Maria-Luisa Tamma; Helmut R Maecke; Jean Claude Reubi
Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.
European journal of pharmacology 2010;644(1-3):257-62.
2010: Alice Laznickova; Milan Laznicek; Frantisek Trejtnar; Helmut R Maecke; Klaus-Peter Eisenwiener; Jean Claude Reubi
Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats.
Anticancer research 2010;30(6):2177-84.
2010: Keelara Abiraj; Rosalba Mansi; Maria-Luisa Tamma; Flavio Forrer; Renzo Cescato; Jean Claude Reubi; Kayhan G Akyel; Helmut R Maecke
Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours.
Chemistry (Weinheim an der Bergstrasse, Germany) 2010;16(7):2115-24.
2009: Flavio Forrer; Jianhua Chen; Melpomeni Fani; Pia Powell; Andreas Lohri; Jan Müller-Brand; Gerhard Moldenhauer; Helmut R Maecke
In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
European journal of nuclear medicine and molecular imaging 2009;36(9):1443-52.
2009: Rosalba Mansi; Xuejuan Wang; Flavio Forrer; Stefan Kneifel; Maria-Luisa Tamma; Beatrice Waser; Renzo Cescato; Jean Claude Reubi; Helmut R Maecke
Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5240-9.
2009: Beatrice Waser; Maria-Luisa Tamma; Renzo Cescato; Helmut R Maecke; Jean Claude Reubi
Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2009;50(6):936-41.
2009: Fabienne Iten; Beat Muller; Christian Schindler; Helmut Rasch; Christoph Rochlitz; Daniel Oertli; Helmut R Maecke; Jan Muller-Brand; Martin A Walter
[(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial.
Cancer 2009;115(10):2052-62.
2008: Jean Claude Reubi; Helmut R Maecke
Peptide-based probes for cancer imaging.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(11):1735-8.
2008: Stephan Good; Martin A Walter; Beatrice Waser; Xuejuan Wang; Jan Müller-Brand; Martin Béhé; Jean Claude Reubi; Helmut R Maecke
Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours.
European journal of nuclear medicine and molecular imaging 2008;35(10):1868-77.
2008: Keelara Abiraj; Hugues Jaccard; Martin Kretzschmar; Lothar Helm; Helmut R Maecke
Novel DOTA-based prochelator for divalent peptide vectorization: synthesis of dimeric bombesin analogues for multimodality tumor imaging and therapy.
Chemical communications (Cambridge, England) 2008;(28):3248-50.
2008: Renzo Cescato; Judit Erchegyi; Beatrice Waser; Véronique Piccand; Helmut R Maecke; Jean E Rivier; Jean Claude Reubi
Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.
Journal of medicinal chemistry 2008;51(13):4030-7.
2008: Jaroslaw B Cwikla; Renata Mikolajczak; Dariusz Pawlak; John R Buscombe; Anna Nasierowska-Guttmejer; Andrzej Bator; Helmut R Maecke; Jerzy Walecki
Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(7):1060-5.
2008: Mihaela Ginj; Hanwen Zhang; Klaus-Peter Eisenwiener; Damian Wild; Stefan Schulz; Hans Rink; Renzo Cescato; Jean Claude Reubi; Helmut R Maecke
New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(7):2019-27.
2008: Melpomeni Fani; João P André; Helmut R Maecke
68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals.
Contrast media & molecular imaging 2008;3(2):67-77.
2008: Axel Heppeler; João P André; Ingeborg Buschmann; Xuejuan Wang; Jean Claude Reubi; Michael Hennig; Thomas A Kaden; Helmut R Maecke
Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting.
Chemistry (Weinheim an der Bergstrasse, Germany) 2008;14(10):3026-34.
2007: Wim J G Oyen; Lisa Bodei; Francesco Giammarile; Helmut R Maecke; Jan Tennvall; M Luster; Boudewijn Brans
Targeted therapy in nuclear medicine--current status and future prospects.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(11):1782-92.
2007: Hanwen Zhang; Jochen Schuhmacher; Beatrice Waser; Damian Wild; Michael Eisenhut; Jean Claude Reubi; Helmut R Maecke
DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
European journal of nuclear medicine and molecular imaging 2007;34(8):1198-208.
2007: Patricia Antunes; Mihaela Ginj; Hanwen Zhang; Beatrice Waser; R P Baum; Jean Claude Reubi; Helmut R Maecke
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?
European journal of nuclear medicine and molecular imaging 2007;34(7):982-93.
2007: Patricia Antunes; Rita Delgado; Michael G B Drew; Vítor Félix; Helmut R Maecke
Copper complexes of new benzodioxotetraaza macrocycles with potential applications in nuclear medicine.
Inorganic chemistry 2007;46(8):3144-53.
2007: Martin Gotthardt; Julliëtte van Eerd-Vismale; Wim J G Oyen; Marion De Jong; Hanwen Zhang; Edgar J Rolleman; Helmut R Maecke; Martin Béhé; Otto Boerman
Indication for different mechanisms of kidney uptake of radiolabeled peptides.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2007;48(4):596-601.
2007: Frantisek Trejtnar; Milan Laznicek; Alice Laznickova; Martin Kopecky; Milos Petrik; Martin Béhé; Jörg Schmidt; Helmut R Maecke; Theodosia Maina; Berthold A Nock
Biodistribution and elimination characteristics of two 111In-labeled CCK-2/gastrin receptor-specific peptides in rats.
Anticancer research 2007;27(2):907-12.
2007: Patricia Antunes; Mihaela Ginj; Martin A Walter; Jianhua Chen; Jean Claude Reubi; Helmut R Maecke
Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.
Bioconjugate chemistry 2007;18(1):84-92.
2007: Helmut R Maecke; J P André
68Ga-PET radiopharmacy: A generator-based alternative to 18F-radiopharmacy.
Ernst Schering Research Foundation workshop 2007;(62):215-42.
2006: Mihaela Ginj; Jörg S Schmitt; Jianhua Chen; Beatrice Waser; Jean Claude Reubi; Marion de Jong; Stefan Schulz; Helmut R Maecke
Design, synthesis, and biological evaluation of somatostatin-based radiopeptides.
Chemistry & biology 2006;13(10):1081-90.
2006: Alicja Hubalewska-Dydejczyk; Katarzyna Fröss-Baron; R Mikołajczak; Helmut R Maecke; Bohdan Huszno; Dorota Pach; Anna Sowa-Staszczak; B Janota; P Szybiński; Jan Kulig
99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience.
European journal of nuclear medicine and molecular imaging 2006;33(10):1123-33.
2006: Stefan Kneifel; Dominik Cordier; Stephan Good; Mihai C S Ionescu; Anthony Ghaffari; Silvia Hofer; Martin Kretzschmar; Markus Tolnay; Christos Apostolidis; Beatrice Waser; Marlene Arnold; Jan Mueller-Brand; Helmut R Maecke; Jean Claude Reubi; Adrian Merlo
Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(12):3843-50.
2006: Helena Uusijärvi; Peter Bernhardt; Frank Rösch; Helmut R Maecke; Eva Forssell-Aronsson
Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(5):807-14.
2006: Ying Ni; Renyi Wu; Wen Xu; Helmut R Maecke; Josef Flammer; Ivan O Haefliger
Effect of cAMP on porcine ciliary transepithelial short-circuit current, sodium transport, and chloride transport.
Investigative ophthalmology & visual science 2006;47(5):2065-74.
2006: Lukas Degen; Daniel Matzinger; juergen Drewe; Sonja Nisslé; Helmut R Maecke; Hans Lengsfeld; Paul Hadvary; Christoph Beglinger
Role of free fatty acids in regulating gastric emptying and gallbladder contraction.
Digestion 2006;74(3-4):131-9.
2006: Flavio Forrer; Christian Waldherr; Helmut R Maecke; Jan Mueller-Brand
Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.
Anticancer research 2006;26(1B):703-7.
2005: Mihaela Ginj; Karin Hinni; Sibylle Tschumi; Stefan Schulz; Helmut R Maecke
Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(12):2097-103.
2005: Flavio Forrer; Helena Uusijärvi; Daniel Storch; Helmut R Maecke; Jan Mueller-Brand
Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(8):1310-6.
2005: Jürgen Grünberg; Ilse Novak-Hofer; Michael Honer; Kurt Zimmermann; Karin Knogler; Peter Bläuenstein; Simon M Ametamey; Helmut R Maecke; P August Schubiger
In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(14):5112-20.
2005: Theodosia Maina; Berthold A Nock; Hanwen Zhang; Anastasia Nikolopoulou; Beatrice Waser; Jean Claude Reubi; Helmut R Maecke
Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(5):823-30.
2005: Flavio Forrer; Jan Mueller-Brand; Helmut R Maecke
Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours.
European journal of nuclear medicine and molecular imaging 2005;32(4):511-2; author reply 513.
2005: Mihaela Ginj; Jianhua Chen; Martin A Walter; Véronique Eltschinger; Jean Claude Reubi; Helmut R Maecke
Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(3):1136-45.
2005: Helmut R Maecke; Michael Hofmann; Uwe Haberkorn
(68)Ga-labeled peptides in tumor imaging.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46 Suppl 1():172S-8S.
2005: Dik J Kwekkeboom; Jan Mueller-Brand; Giovanni Paganelli; Lowell Anthony; Stanislas Pauwels; Larry K Kvols; Thomas M O'dorisio; Roelf Valkema; Lisa Bodei; Marco Chinol; Helmut R Maecke; Eric P Krenning
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46 Suppl 1():62S-6S.
2005: Helmut R Maecke
Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology.
Ernst Schering Research Foundation workshop 2005;(49):43-72.
2004: Anna Płachcińska; Renata Mikołajczak; Helmut R Maecke; Józef Kozak; Andrzej Michalski; Katarzyna Rzeszutek; Jacek Kuśmierek
Efficacy of 99mTc-EDDA/HYNIC-TOC scintigraphy in differential diagnosis of solitary pulmonary nodules.
Cancer biotherapy & radiopharmaceuticals 2004;19(5):613-20.
2004: Hanwen Zhang; Jianhua Chen; Christian Waldherr; Karin Hinni; Beatrice Waser; Jean Claude Reubi; Helmut R Maecke
Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors.
Cancer research 2004;64(18):6707-15.
2004: Anneli Schmitt; Peter Bernhardt; Ola Nilsson; Håkan Ahlman; Lars Kölby; Helmut R Maecke; Eva Forssell-Aronsson
Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2004;45(9):1542-8.
2004: Miklos Pless; Christian Waldherr; Helmut R Maecke; Carlos Buitrago; Richard Herrmann; Jan Mueller-Brand
Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.
Lung cancer (Amsterdam, Netherlands) 2004;45(3):365-71.
2004: Flavio Forrer; Helena Uusijärvi; Christian Waldherr; Marta Cremonesi; Peter Bernhardt; Jan Mueller-Brand; Helmut R Maecke
A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
European journal of nuclear medicine and molecular imaging 2004;31(9):1257-62.
2004: Anna Płachcińska; Renata Mikołajczak; Helmut R Maecke; Andrzej Michalski; Katarzyna Rzeszutek; Józef Kozak; Jacek Kuśmierek
99mTc-EDDA/HYNIC-TOC scintigraphy in the differential diagnosis of solitary pulmonary nodules.
European journal of nuclear medicine and molecular imaging 2004;31(7):1005-10.
2004: Anna Plachcinska; Renata Mikolajczak; Helmut R Maecke; Ewa Mlodkowska; Jolanta Kunert-Radek; Andrzej Michalski; Katarzyna Rzeszutek; Józef Kozak; Jacek Kusmierek
Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a pilot study.
Cancer biotherapy & radiopharmaceuticals 2004;19(2):261-70.
2004: Mihaela Ginj; Helmut R Maecke
Radiometallo-labeled peptides in tumor diagnosis and therapy.
Metal ions in biological systems 2004;42():109-42.
2004: G Meier; Christian Waldherr; Richard Herrmann; Helmut R Maecke; Jan Mueller-Brand; Miklos Pless
Successful targeted radiotherapy with 90Y-DOTATOC in a patient with Merkel cell carcinoma. A Case Report.
Oncology 2004;66(2):160-3.
2003: Anna Płachcińska; Renata Mikołajczak; Helmut R Maecke; Ewa Młodkowska; Jolanta Kunert-Radek; Andrzej Michalski; Katarzyna Rzeszutek; Józef Kozak; Jacek Kuśmierek
Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication.
European journal of nuclear medicine and molecular imaging 2003;30(10):1402-6.
2002: Christian Waldherr; Miklos Pless; Helmut R Maecke; Tilmann Schumacher; Armin Crazzolara; Egbert Nitzsche; Andreas Haldemann; Jan Mueller-Brand
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2002;43(5):610-6.
2002: Tilmann Schumacher; Christian Waldherr; Jan Mueller-Brand; Helmut R Maecke
Kidney failure after treatment with 90Y-DOTATOC.
European journal of nuclear medicine and molecular imaging 2002;29(3):435.
2002: Omer Ugur; Paresh J Kothari; Ronald D Finn; Pat Zanzonico; Shutian Ruan; Ilonka Guenther; Helmut R Maecke; Steven M Larson
Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
Nuclear medicine and biology 2002;29(2):147-57.
2001: M Hofmann; Helmut R Maecke; R Börner; E Weckesser; P Schöffski; L Oei; J Schumacher; M Henze; A Heppeler; J Meyer; H Knapp
Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
European journal of nuclear medicine 2001;28(12):1751-7.
2001: Silvia Hofer; K Eichhorn; Peter Freitag; Jean Claude Reubi; J Muller-Brand; Helmut R Maecke; Adrian Merlo
Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC).
Swiss medical weekly 2001;131(43-44):640-4.
2001: Lukas Degen; Daniel Matzinger; M Merz; Silke Appel-Dingemanse; S Osborne; S Lüchinger; R Bertold; Helmut R Maecke; Christoph Beglinger
Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects.
Alimentary pharmacology & therapeutics 2001;15(11):1745-51.
2001: Christian Waldherr; Miklos Pless; Helmut R Maecke; Andreas Haldemann; Jan Mueller-Brand
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(7):941-5.
2001: Christian Waldherr; Tilmann Schumacher; Miklos Pless; Armin Crazzolara; Helmut R Maecke; Egbert Nitzsche; Andreas Haldemann; Jan Mueller-Brand
Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using.
Nuclear medicine communications 2001;22(6):673-8.
2001: S Moll; Volker Nickeleit; Jan Mueller-Brand; F P Brunner; Helmut R Maecke; Michael J Mihatsch
A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2001;37(4):847-51.
2000: M Bangard; Martin Béhé; Stefan Guhlke; R Otte; Hans Bender; Helmut R Maecke; Hans-Jürgen Biersack
Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
European journal of nuclear medicine 2000;27(6):628-37.
2000: Christian Waldherr; Andreas Haldemann; Helmut R Maecke; Armin Crazzolara; Jan Mueller-Brand
Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2000;12(2):121-3.
1999: Andreas Otte; Richard Herrmann; Axel Heppeler; M Behe; E Jermann; Pia Powell; Helmut R Maecke; J Muller
Yttrium-90 DOTATOC: first clinical results.
European journal of nuclear medicine 1999;26(11):1439-47.
1999: Marta Cremonesi; Mahila Ferrari; stefania zoboli; Marco Chinol; Michael G Stabin; Franco Orsi; Helmut R Maecke; E Jermann; Chris Robertson; Maurizio Fiorenza; Giampiero Tosi; Giovanni Paganelli
Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC.
European journal of nuclear medicine 1999;26(8):877-86.
1999: J P André; Helmut R Maecke; E Tóth; A A Merbach
Synthesis and physicochemical characterization of a novel precursor for covalently bound macromolecular MRI contrast agents.
Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry 1999;4(3):341-7.
1998: Andreas Otte; Jan Mueller-Brand; S Dellas; Egbert Nitzsche; Richard Herrmann; Helmut R Maecke
Yttrium-90-labelled somatostatin-analogue for cancer treatment.
Lancet 1998;351(9100):417-8.
1997: Andreas Otte; E Jermann; M Behe; M Goetze; Heiner C Bucher; H W Roser; Axel Heppeler; Jan Mueller-Brand; Helmut R Maecke
DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.
European journal of nuclear medicine 1997;24(7):792-5.
1997: A Merlo; E Jermann; Oliver Hausmann; R Chiquet-Ehrismann; A Probst; Hans LANDOLT; Helmut R Maecke; Jan Mueller-Brand; Otmar Gratzl
Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas.
International journal of cancer. Journal international du cancer 1997;71(5):810-6.
1997: Ilse Novak-Hofer; Kurt Zimmermann; Helmut R Maecke; H P Amstutz; F Carrel; P August Schubiger
Tumor uptake and metabolism of copper-67-labeled monoclonal antibody chCE7 in nude mice bearing neuroblastoma xenografts.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1997;38(4):536-44.
1996: T C Stoeckli; W Zimmerli; Helmut R Maecke; R Fridrich
Comparison of chemotaxis and superoxide generation of indium-111-oxine- and technetium-99m-HMPAO-labelled granulocytes.
Scandinavian journal of clinical and laboratory investigation 1996;56(4):305-9.
1996: P Magnani; Giovanni Paganelli; Giulio Modorati; F Zito; C Songini; F Sudati; P Koch; Helmut R Maecke; Rosario Brancato; Antonio G Siccardi; Ferruccio Fazio
Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(6):967-71.
1994: W Schwizer; R Fraser; Helmut R Maecke; K Siebold; R Funck; M Fried
Gd-DOTA as a gastrointestinal contrast agent for gastric emptying measurements with MRI.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 1994;31(4):388-93.
1993: A Smith; Roger Alberto; P Blaeuenstein; Ilse Novak-Hofer; Helmut R Maecke; P August Schubiger
Preclinical evaluation of 67Cu-labeled intact and fragmented anti-colon carcinoma monoclonal antibody MAb35.
Cancer research 1993;53(23):5727-33.
1992: W Schwizer; Helmut R Maecke; M Fried
Measurement of gastric emptying by magnetic resonance imaging in humans.
Gastroenterology 1992;103(2):369-76.
1991: Peter Smith-Jones; R Fridrich; T A Kaden; Ilse Novak-Hofer; K Siebold; D Tschudin; Helmut R Maecke
Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1,4,8,11-tetraazacyclotetradec-1-yl)methyl]benzoic acid.
Bioconjugate chemistry 1991;2(6):415-21.
1990: G Ruser; W Ritter; Helmut R Maecke
Synthesis and evaluation of two new bifunctional carboxymethylated tetraazamacrocyclic chelating agents for protein labeling with indium-111.
Bioconjugate chemistry 1990;1(5):345-9.
1989: Helmut R Maecke; A Riesen; W Ritter
The molecular structure of indium-DTPA.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1989;30(7):1235-9.